ERBB2 and breast carcinoma: Another targeted therapy under study was refametinib, an allosteric MEK1/2 inhibitor that showed, in combination with copanlisib and anti-HER2-targeted therapies, an antiproliferative effect when was used in HER2-positive breast cancer cell lines with acquired trastuzumab or lapatinib resistance [70].